Determinants of survival in pulmonary Langerhans’ cell granulomatosis (histiocytosis X)


ABSTRACT: The course of pulmonary Langerhans’ cell granulomatosis (pulmonary LCG) is variable, difficult to predict and ranges from spontaneous remission to progressive respiratory insufficiency and death. To identify the determinants of survival, we performed a survival analysis on 45 patients with pulmonary LCG.

The patients were aged 28±10 yrs (mean±sd) (range 12–62 yrs), 32 males and 13 females, almost exclusively current smokers (96%), and 78% presented symptoms at the time of diagnosis. Diagnosis was made by lung biopsy in 25 patients (56%) and by bronchoalveolar lavage (BAL) analysis in 20 patients (44%). The patients were followed for a median period of 6 yrs (range 1–29 yrs) after the diagnosis. During the period of observation, 33 (73%) patients survived (median follow-up period = 5.8 yrs; range, 1–29 yrs) and 12 (27%) died or underwent lung transplantation (median follow-up period = 8.4 yrs; range, 1.4–16.1 yrs). The median survival was approximately 13 years. A univariate analysis demonstrated that diminished survival was significantly associated with: an older age at diagnosis (p=0.0001); a lower forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio at diagnosis (p=0.005); a higher residual volume/total lung volume (RV/TLC) ratio at diagnosis (p=0.02); and steroid therapy during follow-up (p=0.03). Additional predictive information on mortality was: age >26 yrs (sensitivity 83%, specificity 64%); FEV1/FVC ratio <0.66 (sensitivity 75%, specificity 86%); and a RV/TLC ratio >0.33 (sensitivity 75%, specificity 63%). In multivariate Cox analysis, the combination of factors which gave the best prognostic value was FEV1/FVC ratio and age (p<0.01).

The present findings suggest that adverse prognosis factors at diagnosis in pulmonary Langerhans’ cell granulomatosis include older age, lower FEV1/FVC ratio and higher RV/TLC ratio, with additional predictive information on mortality if aged >26 yrs, FEV1/FVC ratio <0.66, and RV/TLC ratio >0.33.


*Service de Pneumologie et Immuno-allergologie, Hôpital A. Calmette, and INSERM U416 Institut Pasteur, Lille Cedex, France.
**Centre d’Etudes et de Recherche en Informatique Medicale, Faculté de Médecine, Lille, France.

Keywords: Histiocytosis X
interstitial lung disease
Langerhans’ cell granulomatosis lung survival

Received: December 18 1995
Accepted after revision June 16 1996

Pulmonary Langerhans’ cell granulomatosis (pulmonary LCG), also referred to as histiocytosis X, is a rare granulomatous disease of unknown etiology, that represents less than 4% of all forms of interstitial lung disease [1]. The disease occurs almost exclusively in smokers. The course of the disease is variable, difficult to predict, and may range from spontaneous remission to progressive respiratory insufficiency and death [2–7]. In a minority of patients, progressive disease leads to respiratory insufficiency over a period of months to years.

The percentage of deaths can range from 2% [8] to 30% [2–9]. Most authors consider that adverse prognostic factors in pulmonary LCG include: advanced age at diagnosis; prolonged constitutional symptoms; numerous cysts on computed tomography; decreased lung transfer factor for carbon monoxide (TLCO) at diagnosis, recurrent pneumothorax; multisystem generalized disease; and continuation of tobacco consumption [2, 3, 6, 9–13]. Some authors have observed a beneficial response to corticosteroid therapy [2] or chemotherapeutic agents [3]. However, the efficacy of treatment currently used in pulmonary LCG has so far not been demonstrated.

Few investigations have identified the clinical features of pulmonary LCG that are independently associated with a diminished survival. The purpose of this study was to identify the causes of death and the determinants of survival at the time of diagnosis in pulmonary LCG.

Patients and methods

Patients

Forty five patients with pulmonary LCG were included in this study. The time of disease onset was defined as the patient’s recollection of first appearance of chest symptoms (dyspnoea or pneumothorax) or the first documented chest roentgenogram demonstrating interstitial
The pulmonary function tests consisted of standard spirometry using a Medical Graphics 1070 system (St Paul, MN, USA), and lung volumes via body plethysmography using a Medical Graphics 1085 system. Single-breath $L_{CO}$ was measured using the Medical Graphics 1070 system. Results were also expressed as percentage of predicted values [19]. Pulmonary function parameters at the time of diagnosis are presented in table 2 and showed a tendency to low values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), total lung capacity (TLC) and $L_{CO}$/alveolar volume ($V_{A}$) associated with high values of residual volume (RV) and RV/TLC ratio. At the time of diagnosis, 35% of the study subjects had normal pulmonary function; 33% had an obstructive pattern; 27% had a restrictive pattern and 5% had a mixed pattern. In the group of patients who developed a terminal respiratory failure, 88% had an obstructive pattern.

### Statistical analysis

The following parameters were analysed for their prognostic value on survival: age, sex, pulmonary symptoms, cessation of tobacco consumption, ILO profusion category, treatment with corticosteroids, and the functional variables. All analyses were performed with Statistical Analysis System (SAS) software (SAS Institute Inc., Cary, NC, USA). The association between the continuous variables were tested using Spearman's correlation coefficient. For discrete parameters, survival curves were calculated based on the method of Kaplan and Meier [21]. A log rank test [22] was used to determine whether significant differences existed between curves. Risk ratio were calculated using the Mantel [23] estimator. The prognostic value of continuous variables (age and functional parameters) was studied using the Cox [24, 25] proportional hazards model. The graphical method using survival curve estimates based on the residuals was performed to check the validity of the proportional hazard assumption [25]. The parameters significant at the 0.15 level for survival were introduced in a Cox proportional hazards regression analysis of survival, with both forward and best subset selection [26, 27]. Receiver operating characteristic (ROC) analysis was performed to determine cut-off values associated with the mortality for the continuous parameters.
Results

Of 45 patients with pulmonary LCG, the median period of observation from onset of respiratory symptoms was 6 yrs (range 1–29 yrs). During this period of observation, 33 subjects (73%) survived (Group A) and 12 (27%) died or underwent lung transplantation (Group B). The median follow-up period from onset of respiratory symptoms was 5.8 yrs (range 1–29 yrs) in Group A, and 8.4 yrs (range 1.4–16.1 yrs) in Group B.

Nine out of the 12 subjects (Group B) developed a terminal respiratory failure (six died quickly within 2.5 yrs after the diagnosis and three required a lung transplantation). Two patients died due to a nonresectable pulmonary neoplasm (epidermoid carcinoma stage IV diagnosed concurrently with pulmonary LCG, and adeno-carcinoma stage IIIB diagnosed 16 yrs after the diagnosis of pulmonary LCG). The last patient died following a cardiac arrest 12 yrs after the diagnosis of pulmonary LCG. According to these data, it was demonstrated that the subjects with pulmonary LCG had a median survival of approximately 13 yrs from the date of the diagnosis (fig. 1).

Eighteen patients (39%) quit smoking during the follow-up period, a median of 2.8 yrs (range 0–26 yrs) after the time of diagnosis.

Four patients exhibited extrapulmonary involvement with LCG during the follow-up period: two had lymph node involvement at diagnosis, one of whom developed bone lesions during the follow-up period; bone lesions appeared in one other during the follow-up period; and one presented a diabetes insipidus at the time of diagnosis. These four patients survived but the small number did not allow statistical analysis.

Twenty three patients (52%) were treated with immunosuppressive drugs: 20 of these 23 patients were treated with corticosteroids (table 3). Nineteen patients were treated because of severe abnormalities of pulmonary function and four because of systemic complaints. Corticosteroid treatment was given for a median period of 1.1 yrs (range 0.2–8.4 yrs), and was introduced after a median period of 0.1 yrs (range 0–6.9 yrs) from the date of diagnosis.

The effects of the clinical, radiological and functional variables on survival are presented in table 4. A univariate analysis demonstrated that diminished survival was significantly associated with an older age at diagnosis (hazard ratio (HR)=1.12; 95% confidence interval (95% CI)=1.06–1.18; p=0.0001); a lower FEV1/FVC ratio at diagnosis (HR=0.94; 95% CI=0.90–0.98; p=0.005); a higher RV/TLC ratio at diagnosis (HR=1.09; 95% CI=1.01–1.18; p=0.02) and corticosteroid therapy during follow-up (HR=2.42; 95% CI=0.52–11.25; p=0.03). For these adverse prognostic factors, additional predictive information on mortality was provided if age was >26 yrs (sensitivity 83%, specificity 64%); FEV1/FVC ratio <0.66 (sensitivity 75%, specificity 86%) and RV/TLC ratio was >0.33 (sensitivity 75%, specificity 63%). In multivariate Cox analysis, the combination of factors which gave the best prognostic value was FEV1/FVC ratio and age (p<0.01).

Table 4. Effect of clinical and functional variables at the time of diagnosis and of steroid therapy during follow-up on survival of the 45 patients with pulmonary LCG

<table>
<thead>
<tr>
<th>Treatment regimen</th>
<th>Subjects</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>22</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Corticosteroids alone</td>
<td>18</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Corticosteroids and cyclophosphamids</td>
<td></td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Polychemotherapy</td>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Vinblastine and azathioprine</td>
<td></td>
<td></td>
<td>1</td>
</tr>
</tbody>
</table>

§: cyclophosphamide used for 4 and 3 months before death, respectively; ‡: polychemotherapy for 1.5 yrs consisted of 8 courses of etoposide and 1 course of ifosfamide, mitoguazone, vinorelbine and etoposide; *: chlorambucil used for 2.2 yrs; †: vinblastin used for 0.9 yrs and azathioprine for 0.8 yrs.

Table 3. Treatment regimen for the study of subjects with pulmonary Langerhans' cell granulomatosis (LCG)

<table>
<thead>
<tr>
<th>Treatment regimen</th>
<th>Subjects n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticosteroids and cyclophosphamids</td>
<td>25</td>
</tr>
<tr>
<td>Corticosteroids alone</td>
<td>18</td>
</tr>
<tr>
<td>None</td>
<td>22</td>
</tr>
<tr>
<td>Polychemotherapy</td>
<td>1</td>
</tr>
<tr>
<td>Chlorambucil</td>
<td>1</td>
</tr>
<tr>
<td>Vinblastine and azathioprine</td>
<td>1</td>
</tr>
</tbody>
</table>

International Labour Organization. For further definitions see legend to table 2.

Fig. 1. – Actuarial curve for survival from onset of respiratory symptoms for all patients with pulmonary Langerhans' cell granulomatosis (LCG) (n=45). The Kaplan-Meier method was used to estimate the survival distribution.
Table 5. Effect of clinical and functional variables at the time of diagnosis and of steroid therapy during follow-up on evolution to terminal respiratory failure of the 45 patients with pulmonary LCG

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.12</td>
<td>1.05–1.19</td>
<td>0.0005</td>
</tr>
<tr>
<td>Male gender</td>
<td>1.57</td>
<td>0.3–8.25</td>
<td>0.6</td>
</tr>
<tr>
<td>Pulmonary symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VC none</td>
<td>3.69</td>
<td>0.76–17.96</td>
<td>0.11</td>
</tr>
<tr>
<td>Cessation of tobacco consumption</td>
<td>10.57</td>
<td>1.29–86.34</td>
<td>0.03</td>
</tr>
<tr>
<td>Treatment with corticosteroids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VC none</td>
<td>2.44</td>
<td>0.5–11.28</td>
<td>0.03</td>
</tr>
<tr>
<td>IL-2 profusion category</td>
<td>1.7</td>
<td>0.8–4.12</td>
<td>0.16</td>
</tr>
<tr>
<td>FEV1</td>
<td>0.99</td>
<td>0.94–1.00</td>
<td>0.07</td>
</tr>
<tr>
<td>FVC</td>
<td>0.98</td>
<td>0.94–1.03</td>
<td>0.5</td>
</tr>
<tr>
<td>FEV1/FVC ratio</td>
<td>0.95</td>
<td>0.90–0.99</td>
<td>0.03</td>
</tr>
<tr>
<td>TLC</td>
<td>1.02</td>
<td>0.97–1.08</td>
<td>0.4</td>
</tr>
<tr>
<td>RV</td>
<td>1.01</td>
<td>0.99–1.03</td>
<td>0.2</td>
</tr>
<tr>
<td>RV/TLC ratio</td>
<td>1.11</td>
<td>1.02–1.21</td>
<td>0.01</td>
</tr>
<tr>
<td>TVLCO/VA</td>
<td>0.98</td>
<td>0.95–1.00</td>
<td>0.07</td>
</tr>
<tr>
<td>TVLCO/VA &lt;55%</td>
<td>0.21</td>
<td>0.05–0.89</td>
<td>0.03</td>
</tr>
</tbody>
</table>

For definitions see legend to tables 2 and 4.

nine subjects who developed a terminal respiratory failure (table 5). For these nine subjects, $T_{LCO}/V_{A} <55\%$ of the predicted value at the time of diagnosis was significantly associated (HR=0.21; 95% CI=0.05–0.89; p=0.03) with evolution to terminal respiratory failure.

Discussion

The present results indicate that patients with pulmonary LCG have a median survival of approximately 13 yrs from the date of diagnosis and that adverse prognostic factors include an older age, a lower FEV1/FVC ratio, a higher RV/TLC ratio, and steroid therapy during follow-up. Additional predictive information on mortality was demonstrated when age was $>26$ yrs, FEV1/FVC ratio $<0.66$, and RV/TLC ratio $>0.33$ at the time of diagnosis.

The percentage of dead subjects (27%) was similar to that reported by Basset et al. [2] and Sadoun et al. [9]. Friedman et al. [8] reported a lower percentage (2%) but a significant number of patients had persistent abnormalities or experienced subsequent progression. Death was mainly due to terminal respiratory failure, and secondly to the development of a pulmonary neoplasm [13]. In the present series, lung neoplasm occurred concurrently in one patient and 16 yrs later in the second. The percentage of pulmonary malignancies associated with pulmonary LCG is similar to that of Egerler et al., who found 3.5% of pulmonary cancer during the course of pulmonary LCG [4]. Clearly, tobacco consumption is the most important factor for the development of pulmonary neoplasm.

Disseminated LCG with or without pulmonary involvement is thought to have a worse prognosis than pulmonary LCG involving the lung alone [3]. Interestingly, the four subjects with extrapulmonary organs invaded by LCG without severe dysfunction were alive at the end of the follow-up period. However, the small number of these subjects did not permit statistical conclusions to be made and these data should be confirmed in larger studies.

Typically, radiographic abnormalities are bilateral, symmetrical, diffuse and predominate in the upper and middle lobes, with sparing of the costophrenic angles [2]. Nodular lesions, as evaluated by ILO classification, are present in the early stages, whereas cysts and bullae predominate in more advanced disease. Because radiographs are insensitive in detecting small cystic lesions, patients with low ILO profusion might demonstrate severe airway obstruction on pulmonary function tests. Basset and co-workers [28] reported that the degree of dissemination of nodular lesions within the lungs, presence or absence of cysts, diameter of nodular opacities or diameter of lesion had no prognostic value. High-resolution computed tomography (HRCT) has proved to be of considerable value in the diagnosis of pulmonary LCG, and allows a precise identification both of nodular and cystic lesions [29, 30]. However, we were unable to identify the HRCT determinants of survival because only 12 subjects underwent HRCT at the time of diagnosis.

Pulmonary function tests are highly variable during the course of pulmonary LCG. Evidence of airway obstruction is common and usually characteristic of the disease. Decreased FEV1/FVC ratio and increased RV/TLC ratio are a common finding, especially in patients with extensive cystic lesions [31, 32]. The specific factors that were found to be independently associated with survival represent a small portion of markers of disease severity. As previously emphasized in idiopathic pulmonary fibrosis [33], measures of lung function are highly interdependent and the present study only demonstrates that, once the effect of FEV1/FVC ratio is taken into account, the effect of the other measures of lung function in predicting survival is negligible. The fact that severe airway obstruction is associated with a decreased survival may be due to the fact that the diagnosis was made at the end-stage of the disease. Indeed, in the early stage, the granulomas have a strong tendency to occur around bronchioles and are associated with mild restrictive changes and/or reduction in $T_{LCO}$. At the end-stage, cystic lesions of variable size are present and pulmonary function testing commonly demonstrates evidence of airway obstruction, air-trapping and reduced transfer factor.

In the present study, absence of immunosuppressive therapy, mainly steroids, and the continuation of tobacco consumption were not associated with diminished survival. Because of the high rate of spontaneous remission, and the rarity of the disease, there are no reliable data concerning the efficiency of various treatment schedules on survival. Several studies have reported the effects of corticosteroids combined or not with chemotherapeutic agents or combination chemotherapy often used in generalized disease [12, 34]. However, none of these studies have reported the effectiveness of such treatments on survival and on the long-term course of the disease. In the present study, Group B patients (deceased or lung transplanted) had received significantly more treatment and significantly more of them had completely ceased their tobacco consumption compared to Group A patients (survivors). It is likely that subjects who were treated or have completely stopped their tobacco consumption had more advanced pulmonary LCG. Importantly, this study was not established as a treatment trial, and the absence of relationship between survival and treatment or cessation of tobacco consumption should be interpreted cautiously. Clearly, patients with pulmonary LCG should stop smoking. However, although a beneficial effect of smoking cessation on pulmonary LCG has been reported [35], such an effect has never been formally established.
Our results suggest that severe deterioration of pulmonary function at the time of the diagnosis, especially obstructive ventilatory defect, affects survival of patients with pulmonary Langerhans’ cell granulomatosis. These findings raise the intriguing question of the validity of the beneficial effects of an early treatment in severe pulmonary Langerhans’ cell granulomatosis. Future studies and prospective multicentre trials should assess whether identification of clinical, functional and radiological factors, including high resolution computed tomography, at the time of diagnosis and during the first year of follow-up may provide useful information in the management and treatment of pulmonary Langerhans’ cell granulomatosis.

Members of the GEPH:
F. Bart (Bethune, F); A. Benard (Roubaix, F); J.F. Bervar (Arras, F); E. Cardot (Bethune, F); E. Dansin (Lille, F); C. Degvie (Serrang, B); L. Delaunois (Mont-Godinne, B); E. Delepeulle (Lens, F); A. Delobbe (Lille, F); A. Duhamel (Lille, F); A. Dutheil (Roubaix, F); G. Demarq (Valenciennes, F); Ch. Deroubaix (Dunkerque, F); C. Florin (Douai, F); X. Fichecheuelle (Tourcoing, F); F. Fortin (Lille, F); B. Fourquet (Calais, F); J.M. Grosbois (Lille, F); M.ustin (Liege, B); F. Herengt (Arras, F); J.J. Laffite (Lille, F); Y. Lieuran (Arras, F); C.H. Marquette (Lille, F); E. Maetz (Douai, F); B. Mellin (Dunkerque, F); F. Parage (Somain, F); T. Perez (Lille, F); M. Radermecker (Liege, B); Ph. Ramon (Lille, F); D.O. Rodenstein (Bruxelles, B); J.P. Roux (Valenciennes, F); B. Stach (Valenciennes, F); F. Steenhouver (Roubaix, F); J. Soots (Bethune, F); V. Tack (Calais, F); I. Tille-Leblond (Lille, F); A.B. Tonnel (Lille, F); V. Varet (Bethune, F); B. Wallaert (Lille, F); C. Wallaert (Lens, F).

References